Brokerages Expect Cellectis SA (CLLS) Will Post Earnings of -$0.20 Per Share
Equities analysts forecast that Cellectis SA (NASDAQ:CLLS) will report earnings per share (EPS) of ($0.20) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cellectis’ earnings. Cellectis posted earnings of ($0.73) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 72.6%. The firm is scheduled to announce its next earnings report on Monday, November 12th.
According to Zacks, analysts expect that Cellectis will report full-year earnings of ($0.78) per share for the current fiscal year. For the next year, analysts anticipate that the firm will post earnings of ($1.14) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for Cellectis.
Cellectis (NASDAQ:CLLS) last released its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.45. The business had revenue of $8.34 million during the quarter, compared to the consensus estimate of $9.43 million. Cellectis had a negative net margin of 281.38% and a negative return on equity of 25.46%.
Cellectis stock traded down $0.77 during mid-day trading on Friday, reaching $26.20. The company’s stock had a trading volume of 87,124 shares, compared to its average volume of 155,999. The company has a market cap of $1.12 billion, a P/E ratio of -9.42 and a beta of 1.84. Cellectis has a 12 month low of $22.62 and a 12 month high of $38.85.
Hedge funds have recently made changes to their positions in the business. JBF Capital Inc. acquired a new stake in Cellectis in the second quarter valued at $1,697,000. ARK Investment Management LLC lifted its stake in Cellectis by 178.8% in the second quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock valued at $6,910,000 after acquiring an additional 156,666 shares during the last quarter. UBS Group AG lifted its stake in Cellectis by 143.1% in the first quarter. UBS Group AG now owns 15,383 shares of the biotechnology company’s stock valued at $485,000 after acquiring an additional 9,054 shares during the last quarter. Vident Investment Advisory LLC lifted its stake in shares of Cellectis by 30.3% during the 2nd quarter. Vident Investment Advisory LLC now owns 80,527 shares of the biotechnology company’s stock worth $2,278,000 after buying an additional 18,730 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Cellectis during the 2nd quarter worth about $845,000. Hedge funds and other institutional investors own 27.10% of the company’s stock.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Further Reading: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.